Maxion Therapeutics

Executive Summary

Maxion Therapeutics is a privately held UK biotech company pioneering the development of first-in-class and best-in-class protein therapeutics for previously untreatable ion channel- and GPCR-driven diseases. Founded in 2020 and headquartered in Cambridge, the company leverages its proprietary KnotBody® technology, which combines the stability and specificity of knottin peptides with antibody-like properties, to target challenging membrane proteins. Ion channels and GPCRs represent a large, validated class of drug targets, yet have been historically difficult to modulate with conventional biologics or small molecules. Maxion's approach aims to unlock these targets, addressing significant unmet medical needs in therapeutic areas such as pain, autoimmune disorders, and metabolic diseases. While the company remains in a pre-revenue stage, its innovative platform has the potential to generate multiple product candidates. Maxion is currently advancing its pipeline toward preclinical development, with a focus on validating its lead programs in disease-relevant models. Given the early-stage nature of the company, key milestones will revolve around platform validation, candidate selection, and securing funding to support IND-enabling studies. The KnotBody platform differentiates Maxion by enabling high-affinity, selective modulation of difficult targets, which could attract partnership interest from larger pharmaceutical companies. Over the next 12-18 months, the company is expected to disclose preclinical proof-of-concept data and may initiate a Series A or B financing round to advance its most promising assets toward clinical trials. With a robust technology platform and a clear focus on high-value targets, Maxion represents an attractive opportunity in the biologics space, though significant de-risking remains ahead.

Upcoming Catalysts (preview)

• TBDPreclinical Proof-of-Concept Data for Lead KnotBody Program40% success
• Q3 2026Series A or B Financing Round70% success
• TBDPharmaceutical Partnership or Licensing Deal20% success